Variants of uncertain significance in breast cancer-related genes: Real-world implications for a clinical conundrum. Part one: Clinical genetics recommendations

Seminars in Oncology

Volumn 38, Issue 4, 2011, Pages 469-480

  Miller Samuel, Susan ^e   McDonald, Deborah J ^a   Weitzel, Jeffrey N ^a   Santiago, Ferdy ^b   Martino, Martin A ^b   Namey, Tara ^b   Augustyn, Annmarie ^b   Mueller, Rebecca ^c   Forman, Andrea ^d   Bradbury, Angela R ^d   Morris, Gloria J ^f,g,h  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b LeHigh Valley Cancer Center   (United States)

^c ARCADIA UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f Hematology and Oncology Associates of Northeastern PA PC   (United States)

^g Family Risk Assessment Program   (United States)

^h Janet Weis Children s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; BREAST CANCER RELATED GENE; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; INTRADUCTAL CARCINOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE; VARIANT OF UNCERTAIN SIGNIFICANCE;

AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENETICS, MEDICAL; HUMANS; MIDDLE AGED; PEDIGREE; PRACTICE GUIDELINES AS TOPIC;

EID: 79961003017     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.008     Document Type: Article

References (45)

1. Domchek S, Weber BL. Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 2008;26:16-17.
2. Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat. 2008;29:1265-72.
3. Gómez García EB, Oosterwijk JC, Timmermans M, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res. 2009;11:R8.
4. O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology 2009;18:1088-1096.
5. Couch FJ, Rasmussen LJ, Hofstra R, et al. Assessment of functional effects of unclassified genetic variants. Hum Mutat. 2008;29:1314-1326.
6. Vos J, van Asperen CJ, Wijnen JT, Stiggelbout AM, Tibben AD. Disentangling the Babylonian speech confusion in genetic counseling: an analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic. Genet Med. 2009;11:742-9.
7. van Dijk S, Otten W, Timmermans DR, et al. What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med. 2005;7:239-45.
8. Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6:107-13.
9. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-9.
10. http://www.nccn.org/professionals/physician-gls/PDF/genetics-screening. pdf.
11. Constantinidou A, Jones RL, Reis- Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Exp Rev Anticancer Ther. 2010;10:1197-213.
12. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692-5.
13. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-89.
14. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer predisposition genes. Am J Hum Genet. 2007;81:873-83. (Pubitemid 47580242)
15. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-30.
16. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutation in BRCA1 and BRCA2. Science. 2003;302:643-6. (Pubitemid 37310920)
17. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735-42.
18. The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-6.
19. Brose MS, Timothy R. Rebbeck TR, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94: 1365-72.
20. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42:711-9.
21. Nichols KE, Heath JA, Friedman D, et al. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. J Clin Oncol. 2003;21:4505-9.
22. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-75. (Pubitemid 37430500)
23. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297:2587-95.
24. Hu N, Wang C, Han XY, et al. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene. 2004;23:852-8.
25. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250-6.
26. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-7. (Pubitemid 30326453)
27. Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Cancer Netw. 2007;5:676-701.
28. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8:562-94.
29. del Valle J, Feliubadalo L, Nadal M, et al. Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat. 2010;122:733-43.
30. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13-27.
31. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250-6.
32. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. In: Grunberg SM, ed. 45th Annual Meeting of the American Society of Clinical Oncology. Vol 27. Orlando, FL: ASCO Publications; 2009:7s.
33. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. (Pubitemid 46535708)
34. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer. 1994;73:643-51. (Pubitemid 24046606)
35. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-86. (Pubitemid 20026073)
36. Stopfer J, Domchek S. Evaluation and management of women with BRCA1/2 mutations. http://www.cancernetwork.com/gynecologiccancer/content/article/10165/ 105318. Oncology. 2005;19.
37. National Cancer Institute. BRCA1 and BRCA2: cancer risk and genetic testing. Retrieved November 20, 2010 from http://www.cancer.gov/cancertopics/ factsheet/Risk/BRCA.
38. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;96:222-6. (Pubitemid 39612440)
39. Saam J, Burbridge LA, Bowles K, et al. Decline in rate of BRCA 1/2 variants of uncertain significance: 2002-2008. Myriad for Professionals. Retrieved November 22, 2010 from https://www.myriadpro.com/resources/myriad- publications.
40. Vink GR, van Asperen CJ, Devilee P, Breuning MH, Bakker E. Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counseling, a proposal for guidelines. Eur J Hum Genet. 2005:13:525-7. (Pubitemid 40691391)
41. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis. Version 1.2011. www.nccn.org/professionals/physician-gls/pdf/breast-screening.pdf. Accessed May 23, 2011.
42. Van Dijk S, van Asperen CJ, Jacobi CE, et al. Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genet Test. 2004;8:235-9.
43. Peshkin BN, DeMarco TA, Brogan BM, et al. BRCA1/2 testing: complex themes in result interpretation. J Clin Oncol. 2001;19:2555-65.
44. Nelson DR. 'A variant of uncertain significance' and the proliferation of human disease gene databases. Hum Genom. 2005;2:70-4.
45. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening, Version 2.2011. http://www.nccn.org/ professionals/physician-gls/pdf/colorectal-screening.pdf Accessed May 23, 2011.